Loading…
Savara Inc. is projected to rise to $6.71 by 2027, a +29% move from its current price of $5.21. SVRA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.07 | $5.21 | $5.35 | -0.02% |
| May 30 | $5.01 | $5.21 | $5.41 | -0.05% |
| May 31 | $4.97 | $5.21 | $5.45 | -0.07% |
| Jun 1 | $4.93 | $5.20 | $5.49 | -0.10% |
| Jun 2 | $4.90 | $5.20 | $5.53 | -0.12% |
| Jun 3 | $4.87 | $5.20 | $5.56 | -0.15% |
| Jun 4 | $4.84 | $5.20 | $5.59 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.84 | $5.20 | $5.59 | -0.17% |
| Week 2 | $4.69 | $5.19 | $5.74 | -0.35% |
| Week 3 | $4.58 | $5.18 | $5.86 | -0.52% |
| Week 4 | $4.49 | $5.17 | $5.97 | -0.69% |
| Week 5 | $4.40 | $5.16 | $6.06 | -0.87% |
| Week 6 | $4.33 | $5.16 | $6.14 | -1.04% |
| Week 7 | $4.26 | $5.15 | $6.21 | -1.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Savara Inc. is a healthcare company focused on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Savara Inc. (SVRA) operates in Healthcare as a clinical stage biopharmaceutical company focused on rare respiratory diseases in the United States. The stock currently trades at $5.02 with a market capitalization of $1.03B, and it ranks 2525 by market cap.
The near-term technical picture shows neutral sentiment, with RSI14 at 50, SMA50 at $5.29 and SMA200 at $4.88.
The price outlook from the forecast is bullish over the long horizon, with the avg price rising through multiple years and ROIs climbing to 614.3% by 2050; sentiment turns bullish in 2027 onward.
A major floor 21.0% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 12.7% above — a clean break opens room to run.
A major ceiling 24.0% above — clearing it would confirm fresh momentum.
Key SVRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SVRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.10 | Buy | $5.11 | Buy |
| MA 10 | $5.07 | Buy | $5.09 | Buy |
| MA 20 | $5.12 | Buy | $5.14 | Buy |
| MA 50 | $5.29 | Sell | $5.27 | Sell |
| MA 100 | $5.47 | Sell | $5.26 | Sell |
| MA 200 | $4.91 | Buy | $4.90 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.03 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 52.74 | Neutral |
| Williams %R (14) | -10.91 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -0.38 | Sell |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 89.09 | Sell |
| TRIX (15) | -0.26 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 54.30 | Neutral |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 5.15 | Buy |
| ADX (14) | 9.87 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 50. The 50-day simple moving average sits at $5.29 and the 200-day simple moving average at $4.88.
Immediate support is at $4.72 and resistance at $6.07. The 30-day price range is $4.17 to $6.04.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.72 | $5.21 | $6.82 | 0% | Neutral | |
| $5.33 | $6.71 | $8.95 | +29% | Bullish | |
| $5.88 | $7.60 | $10.50 | +46% | Bullish | |
| $6.58 | $8.70 | $12.36 | +67% | Bullish | |
| $6.63 | $8.95 | $13.02 | +72% | Bullish | |
| $6.73 | $9.24 | $13.72 | +77% | Bullish | |
| $7.59 | $10.61 | $16.04 | +104% | Bullish | |
| $8.30 | $11.78 | $18.12 | +126% | Bullish | |
| $9.72 | $14.01 | $21.89 | +169% | Bullish | |
| $10.73 | $15.69 | $24.87 | +201% | Bullish | |
| $14.78 | $23.07 | $38.87 | +343% | Bullish | |
| $22.68 | $39.63 | $72.96 | +661% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.72 | $5.21 | $6.13 | +0.00% |
| June 2026 | $4.41 | $5.17 | $6.22 | -0.69% |
| July 2026 | $4.30 | $5.09 | $6.20 | -1.57% |
| August 2026 | $4.38 | $5.22 | $6.42 | +2.39% |
| September 2026 | $4.38 | $5.24 | $6.51 | +0.57% |
| October 2026 | $4.24 | $5.11 | $6.38 | -2.63% |
| November 2026 | $4.27 | $5.16 | $6.50 | +1.13% |
| December 2026 | $4.44 | $5.39 | $6.82 | +4.30% |
Click any year to see its month-by-month SVRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SVRA is projected to trade between $4.72 and $6.82, averaging $5.21 — a potential gain of 0% from today's $5.21. A consolidation phase looks the most probable path here.
Savara Inc.'s 2027 outlook centres on $6.71, within a $5.33 to $8.95 range. That is up +29% on the projected 2026 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2028, SVRA could reach as high as $10.50, with a base case around $7.60 and support toward $5.88 — roughly +46% from $5.21. Buyers look set to stay in control over this stretch.
Expect SVRA to range from $6.58 to $12.36 through 2029. The $8.70 average target implies a +67% move from current prices. That is up +14% on the projected 2028 average. Momentum favours further upside here.
The SVRA price prediction for 2030 points to an average of $8.95 (low $6.63, high $13.02) — a potential gain of +72% on today's $5.21. Buyers look set to stay in control over this stretch.
In 2031, SVRA is projected to trade between $6.73 and $13.72, averaging $9.24 — a potential gain of +77% from today's $5.21. That is up +3% on the projected 2030 average. Momentum favours further upside here.
Savara Inc.'s 2032 outlook centres on $10.61, within a $7.59 to $16.04 range. That is up +15% on the projected 2031 average. That marks a +104% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SVRA could reach as high as $18.12, with a base case around $11.78 and support toward $8.30 — roughly +126% from $5.21. Momentum favours further upside here.
Expect SVRA to range from $9.72 to $21.89 through 2034. The $14.01 average target implies a +169% move from current prices. That is up +19% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The SVRA price prediction for 2035 points to an average of $15.69 (low $10.73, high $24.87) — a potential gain of +201% on today's $5.21. Momentum favours further upside here.
In 2040, SVRA is projected to trade between $14.78 and $38.87, averaging $23.07 — a potential gain of +343% from today's $5.21. That is up +47% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Savara Inc.'s 2050 outlook centres on $39.63, within a $22.68 to $72.96 range. That is up +72% on the projected 2040 average. That marks a +661% change versus current levels. Momentum favours further upside here.
Investing $1,000 in SVRA today (≈ 191.93858 SVRA) could be worth
$7,607.15
+$6,607.15 (+661%) by 2050 · US Dollar
Based on the average projected SVRA price of $39.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SVRAwould be worth at today's price.
$1,000 invested in SVRA on May 27, 2025 (≈ 515.463902 SVRA) would be worth
$2,685.57
+$1,685.57 (+168.6%) today · 2.69× · US Dollar
Based on a SVRA entry price of $1.94 vs. today's $5.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.08 | $1,025.59 | +2.6% |
| 1 month ago | $5.16 | $1,009.69 | +1.0% |
| 3 months ago | $5.97 | $872.7 | -12.7% |
| 6 months ago | $6.29 | $828.3 | -17.2% |
| 1 year ago | $1.94 | $2,685.57 | +168.6% |
| All time (5.0y) ago | $1.81 | $2,878.45 | +187.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SVRA forecast.
Our base-case forecast reaches $10.00 around 2032.
Implied market cap at $10.00: $2.05B
The multi-year forecast shows SVRA rising from a 2026 average price of $5.02 to higher levels in subsequent years, with a bull case developing from 2027 onward.
By 2030 the average price is forecast at $8.41 with a max of $12.34 and a 67.5% ROI, and the path continues higher through 2035, 2040 and 2050. The 2040 forecast lists an average price of $21.26 with a max of $36.31 and a 323.6% ROI, while the 2050 forecast shows an average of $35.86 and a max of $67.08, with a 614.3% ROI. Overall sentiment is BULLISH for the longer horizon, with 2026 remaining NEUTRAL.
These figures are estimates and not guarantees.
Tap a question to reveal the answer.
2030: min $6.18, avg $8.41, max $12.34, ROI 67.5%, sentiment BULLISH.
The forecast shows a bullish trend from 2027 onward with rising averages and ROI up to 614.3% by 2050, though 2026 is neutral. These are estimates, not guarantees.
The 2050 max forecast is $67.08, so a price of $50 could fall within the max scenario, but it is not guaranteed.
RSI14 is 50, SMA50 is $5.29, SMA200 is $4.88. Support is $4.72 and resistance is $6.07. The 30-day range is $4.17 to $6.04.
Savara focuses on rare respiratory diseases in the United States. Lead product molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis; founded in 2007 and headquartered in Langhorne, Pennsylvania.
Savara Inc. Community Discussion
0Share your Savara Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.